Low-Dose Hepatitis B Vaccine

Lee, Chin‐Yun; Hwang, Lu Yu; Beasley, R. Palmer

doi:10.1016/s0140-6736(89)93018-3

Cited by 13 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the same period, another study group, Beasley et al . at Taipei Municipal Women and Children Hospital, Mackay Memorial Hospital and the Washington Medical Research Unit in Taipei, also conducted a series of similar studies 18–21 . The results from these studies showed that, with HBIG coverage from birth, the timing of the start of vaccination does not seem to be of importance within the first month of life.…”

Section: Clinical Trials Of the Hepatitis B Vaccinementioning

confidence: 99%

Legend of hepatitis B vaccination: The Taiwan experience

Chan

Lee

2004

J of Gastro and Hepatol

View full text Add to dashboard Cite

Hepatitis B, a disease entity currently affecting more than 350 million persons worldwide, is also a serious health problem in Taiwan. Liver cirrhosis and hepatoma, which are both closely correlated with hepatitis B, are among the 10 leading causes of death in Taiwan. A mass hepatitis B vaccination program, conducted by the government of Taiwan, was started in 1984. Prior to this vaccination program, a series of viral epidemiological surveys, transmission pattern studies, and pilot immunization trials proved the clinical, economic, and strategic benefits of mass immunization, thus providing the impetus for the implementation of this mass vaccination program. The success of this program has led to a decline in hepatitis B carrier rates among children in Taiwan from 10% to <1%. Furthermore, the mortality rate of fulminant hepatitis in infants and the annual incidence of childhood hepatoma have also decreased significantly in recent years. This is one of the most remarkable success stories in the field of public health.

show abstract

Section: Clinical Trials Of the Hepatitis B Vaccinementioning

confidence: 99%

Legend of hepatitis B vaccination: The Taiwan experience

Chan

Lee

2004

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Although 3 and 5 pg dosages can also give similarly high PEs when administered with HBIG [Lee, 1989;Ip et al, 1989;Theppisai et al, 19881, such lower dosages (including 2.5 pg) show a trend towards giving more variable and noticeably lower PEs than higher dosages, especially when there is no simultaneous administration of HBIG [Lee, 1989;Xu et al, 1985;Ip et al, 1989;Lee et al, 1989;Lin et al, 1987;Assateerawatt et al, 19911. In some studies, all with plasma-derived vaccines, even doses 210 pg have conferred relatively poor PE when administered without HBIG at birth [Xu et al, 1985;Delage et al, 1988;Wheeley et al, 1990;Chotard et al, 19921.…”

Section: Resultsmentioning

confidence: 99%

“…Similarly if vaccine dosages are compared in the range of 10-20 pg when administered with HBIG, the PE for 10 pg is virtually as good as the PE for 20 pg . This was confirmed in another study with plasma-derived vaccines administered without HBIG being given at birth which showed little difference in PE, ittvdosages varying between 10 and 30 pg [Liu et al, 19911. Although comparisons of results from different studies are fraught with statistical difficulties, it is noted that the PEs for vaccine dosages 210 pg are often * 95% both with HBIG [Lee et al, 1991a;Beasley et al, 1983;Poovorawan et al, 1992;Pongpipat et al, 19891, and without HBIG [Poovorawan et al, 19921. Although 3 and 5 pg dosages can also give similarly high PEs when administered with HBIG [Lee, 1989;Ip et al, 1989;Theppisai et al, 19881, such lower dosages (including 2.5 pg) show a trend towards giving more variable and noticeably lower PEs than higher dosages, especially when there is no simultaneous administration of HBIG [Lee, 1989;Xu et al, 1985;Ip et al, 1989;Lee et al, 1989;Lin et al, 1987;Assateerawatt et al, 19911. In some studies, all with plasma-derived vaccines, even doses 210 pg have conferred relatively poor PE when administered without HBIG at birth [Xu et al, 1985;Delage et al, 1988;Wheeley et al, 1990;Chotard et al, 19921. Furthermore, in a study where HBIG was administered at birth, followed by two different vaccination schedules with a plasma-derived vaccine, the observed PEs were only 81% and 85% using 20 pg and 10 pg doses, respectively, whereas in a subsequent study a 5 pg dose of recombinant vaccine with HBIG at birth gave a PE of 92% [Stevens et al, 19921.…”

Section: Effect Of Dosage On Pementioning

confidence: 99%

Protective efficacy of hepatitis B vaccines in neonates

André¹,

Zuckerman

1994

Journal of Medical Virology

153

View full text Add to dashboard Cite

A literature search was carried out to investigate the factors that influence the protective efficacy (PE) of hepatitis B vaccines when given to neonates of hepatitis B surface antigen and e antigen positive mothers. Hepatitis B vaccines with either high or low antigen doses are very effective in preventing chronic hepatitis B infection in neonates at risk, but there is evidence that with lower dosages simultaneous use of hepatitis B immune globulin (HBIG) administration is more important than with higher dosages to elicit good protection (PE > or = 90%). There is also a tendency for lower dosages to confer high PE less consistently, with noticeably greater numbers of chronic surface antigen carriers in neonates who received a complete vaccination course. Furthermore vaccination courses with higher vaccine dosages give high PEs, without concomitant HBIG administration at birth, provided that the first vaccine dose is given at birth and that the second dose follows within 2 months.

show abstract

“…In 1986, a new Hepatitis B vaccine was obtained by genetic engineering. Its efficacy (85%-95%) [10] is identical to that of the previous vaccine derived from human plasma, and its side-effects and adverse reactions are mild or benign.…”

Section: Simulation Of a Hepatitis B Epidemic In Spainmentioning

confidence: 90%

Mathematical Models for the Analysis of Hepatitis B and AIDS Epidemics

2000

View full text Add to dashboard Cite

Esta es la versión de autor del artículo publicado en: This is an author produced version of a paper published in: AbstractContinuous simulation mathematical models are proposed for two different epidemic situations: Hepatitis B in a cohort of newborns followed for life, and one of the danger groups in the current AIDS epidemic.The paper describes the rational behind the systems of differential equations used to model both situations, and the way to test alternative policies, such as vaccination, preventive measures, or the effects of new drugs on AIDS.

show abstract

Low-Dose Hepatitis B Vaccine

Cited by 13 publications

References 2 publications

Legend of hepatitis B vaccination: The Taiwan experience

Legend of hepatitis B vaccination: The Taiwan experience

Protective efficacy of hepatitis B vaccines in neonates

Mathematical Models for the Analysis of Hepatitis B and AIDS Epidemics

Contact Info

Product

Resources

About